HC Bioscience appoints Simon Tsang Ph.D as Chief Business Officer

Dr. Tsang brings more than two decades of industry experience and a proven track record of building innovation-driven businesses and pipelines. His expertise spans program development, strategic planning, focused dealmaking and efficient integration, making him a valuable addition to HC Bioscience’s leadership team, the company said.

Leslie Williams, CEO and Founder of HC Bioscience, said: “Simon’s combination of business acumen and scientific knowledge is a tremendous asset to our team. His leadership will be critical as we advance our leading program in hemophilia toward clinical trials and continue to develop breakthrough treatments for genetically defined diseases, including Duchenne muscular dystrophy and cancer.”

Dr. Tsang said, “I am excited to join HC Bioscience and contribute to the mission of transforming genetic medicine with first-in-class tRNA-based medicines. The team’s dedication and innovative approach to protein editing have the potential to treat a broad range of genetically defined diseases. I look forward to helping drive the strategic advancement of this novel therapeutic modality and bringing breakthrough treatments to patients.”

About Simon Tsang, Ph.D.

HC Bioscience said that prior to joining the company, Dr. Tsang played a key role in a wide range of transactions focused on innovative therapies and played a key role in defining corporate strategies across many therapeutic areas. His previous roles include Vice President, Company Development at TESARO, Head of Oncology Partnering and Strategy at MedImmune and Director, Corporate Development at Amgen. Dr. Tsang was most recently an Operating Partner at Pivotal BioVenture Partners, where he has served as Chief Business Officer for several biotech companies.

Dr. Tsang received a bachelor’s degree in molecular biology from the University of California, San Diego and a doctorate in biophysics from Harvard.

About HC Bioscience, Inc..

HC Bioscience is committed to improving the lives of patients by developing first-in-class tRNA-based therapies that address a broad spectrum of genetically defined diseases and cancers. Our anticodon-engineered tRNAs transcribe nonsense mutations that would otherwise result in truncated, nonfunctional proteins. This gene-agnostic approach is the basis for a universal drug platform with the potential to treat many mutated genes with the same therapy. Our pipeline includes a lead program in severe hemophilia A and programs in Duchenne muscular dystrophy and cancer.